# To the pancreatic cancer cells learning how to die

> Introduction: a letter to a microscopic enemy

- Author: Maxime Marquette
- Publisher: MadMax (https://mad-max.co)
- Section: Open letter
- Published: 2026-07-04
- Canonical URL: https://mad-max.co/en/article/aux-cellules-du-cancer-du-pancreas-qui-apprennent-a-mourir

## Introduction: a letter to a microscopic enemy

### Why I'm writing to a cancer

Dear **pancreatic cancer cell**, this is an odd letter, I admit, addressed not to a human but to an invisible enemy that **science** may have just cracked open. **Researchers** have uncovered a family of experimental compounds, dubbed **PCAIs**, capable of pushing you into self-destruction in the lab, a mechanism that had never before been exploited this effectively against you, according to a study reported on **June 29, 2026** by **ScienceDaily**.

I write to you with caution, because I know you are tough: **pancreatic cancer** remains one of the most feared diagnoses in **oncology**, with a survival rate that stays historically low, largely because you are detected too late and resist most conventional treatments. But this time, scientists appear to have found a crack in your survival strategy.

### What this letter is not

Let me be clear from the outset: this letter is not an announcement of a cure, nor a promise of a miracle **treatment**. It is the careful, plain-language account of a **laboratory discovery**, still far from **patients**, but interesting enough to deserve a simple explanation, without grandiosity and without false cheer.

Throughout this letter, I will stay faithful to the published facts, citing my sources and relentlessly reminding readers of the limits of this research, because the worst disservice one could do to **families** affected by this disease would be to sell them poorly calibrated hope.

*I deeply believe that honest science communication must know how to say "this is promising" without ever saying "this is solved," and that nuance, however frustrating it may be for a reader in a hurry, is in my view the only ethical stance in the face of such a cruel disease.*

## What the PCAI compounds actually are

### A code name for a targeted weapon

The **PCAIs**, or **polyisoprenylated cysteinyl amide inhibitors** by their full scientific name, are not new to laboratories: variants of this family of molecules have been studied for more than a decade against various cancers, including prostate cancer, as shown by older work published on **PubMed**. But the version tested in 2026, in particular the compound named **NSL-YHJ-2-27**, shows unprecedented effectiveness against pancreatic cells, according to the journal **Oncotarget**, which published the source study on June 3, 2026.

This compound specifically targets a biological modification called **farnesylation**, a process that the **KRAS** protein depends on, notoriously mutated in the vast majority of pancreatic cancers and responsible for making these tumors particularly hard to treat with existing therapies.

### A counterintuitive strategy: pushing instead of braking

Unlike the usual approach of **blocking** the signals that make a tumor proliferate, **researchers** at **Florida A&M University** in Tallahassee found that **PCAIs** do the opposite: they **overactivate** the **MAPK** and **PI3K/AKT** signaling pathways to a breaking point, triggering an internal short circuit that pushes the **cancer cell** toward **apoptosis**, or programmed cell death.

This mechanism, documented in black and white in the **Oncotarget** publication, illustrates a simple but elegant idea: instead of shutting off a cancerous car's engine, you push it past its **red line** until it explodes from the inside, an image several science communicators have used to explain the discovery to the general public.

*As a non-scientist trying to explain this simply, I find it fascinating that a cancer could be defeated not by fighting it head-on but by turning its own overactivity against itself, almost like a judoka redirecting an opponent's force.*

## The precise results obtained in the lab

### Over 90 percent of migration blocked

The figure that has grabbed the most attention from science media is this one: at a concentration of just **1 micromolar**, the compound **NSL-YHJ-2-27** blocked more than **90 percent of the migration capacity** of the pancreatic **cancer cells** tested in the lab, a result reported by both **ScienceDaily** and **Medical Daily** in their respective late-June and early-July 2026 write-ups.

This **migration** capacity is crucial to understand: it is what allows **cancer cells** to spread to other organs, a phenomenon called **metastasis**, responsible for most deaths linked to **pancreatic cancer**. Blocking migration is not the same as curing the primary tumor, but it could, in theory, limit its deadly spread.

### Selective toxicity, not universal toxicity

Another key element reported by the **researchers**: the concentrations that trigger **apoptosis** in **cancer cells** do not cause equivalent **toxicity** in the **healthy cells** tested in parallel. This selectivity, if confirmed in more complex models, would be a major asset, since one of the great problems with conventional **chemotherapies** remains precisely their inability to clearly distinguish diseased cells from healthy ones.

The **researchers** also tested the compounds on **three-dimensional tumor spheroids**, laboratory structures that mimic the reality of a tumor far more closely than simple flat-surface cell cultures, and observed that the **treatment** caused these structures to disintegrate and increased the number of cells undergoing **apoptosis**.

*I think this methodological rigor deserves credit — testing not only isolated cells but also three-dimensional structures closer to tumor reality — because too many promising cancer discoveries collapse precisely when moving from a petri dish to a more complex model.*

## The biological mechanism explained simply

### Oxidative stress and activated caspases

On the biochemical level, **researchers** observed that cells treated with **PCAIs** produced higher levels of **reactive oxygen species**, a significant cellular stress, while also activating enzymes called **caspases**, considered the molecular executioners tasked with carrying out the self-destruction program once it is triggered.

They also found a marked increase in the **BAX** protein, known for its pro-apoptotic role, meaning it actively promotes programmed cell death when a cell detects a level of damage its own internal monitoring mechanisms judge irreparable.

### The disruption of the cell's internal skeleton

Another documented effect: the disruption of **actin filaments**, which form a kind of internal skeleton for the cell and are essential to its ability to move. By disorganizing this architecture, **PCAIs** also limit the **invasion** of surrounding tissue by **cancer cells**, a phenomenon distinct from but complementary to **migration** itself.

This dual effect, on both cell survival and mobility, largely explains why this research has generated so much interest: few experimental compounds can act simultaneously on these two distinct biological fronts within the same lab model.

*At this stage, I remain a cautious communicator rather than an unreserved enthusiast, because cell biology is full of mechanisms that look appealing on paper but don't always survive the test of human clinical trials.*

## The crucial limits nobody should forget

### Research that is still purely preclinical

It bears repeating as clearly as possible: this research remains at a **preclinical** stage, meaning it has only been tested on lab cell cultures, not on **animal models** and certainly not yet on human **patients**. **Medical Daily** explicitly stresses this point in its write-up, reminding readers that the path toward possible clinical application remains long.

The typical path for an experimental compound to become a **treatment** available at the pharmacy generally involves tests on **animal models**, then **phase I clinical trials** to assess safety in humans, followed by phases II and III to measure real-world effectiveness, a process that typically spans **ten to fifteen years**, even when early results are encouraging.

### Why caution is not pessimism

This methodological caution is not an exercise in gratuitous pessimism: it reflects an unforgiving statistical reality in cancer research, where the vast majority of laboratory-promising compounds ultimately fail in **clinical trials**, often due to unforeseen **toxicity** or lower effectiveness in humans than in simplified cell models.

Recalling these limits in no way diminishes the scientific value of the discovery: it simply places it honestly in context, between the legitimate enthusiasm of **researchers** for a new mechanism and the patience required before such a mechanism might one day become an approved drug.

*I believe that this honesty about timelines, however disappointing for someone hoping for a quick fix, is precisely what distinguishes responsible science journalism from a mere relay of unverified commercial hopes.*

## Why pancreatic cancer remains so hard to fight

### A diagnosis that is too often late

**Pancreatic cancer** ranks among the deadliest cancers precisely because it is rarely detected at an early stage: symptoms, often vague, like abdominal pain or unexplained weight loss, typically only appear once the disease is already advanced, severely limiting available treatment options.

According to data generally cited by major **oncology** research organizations, including the American **National Cancer Institute**, five-year survival rates for this cancer remain among the lowest of all solid tumors, a fact that explains the scientific urgency of finding new therapeutic approaches like the one involving **PCAIs**.

### The genetic resistance of the KRAS mutation

The mutation of the **KRAS** gene, present in a large majority of pancreatic tumors, has long been considered by **researchers** an almost impossible therapeutic target to hit directly, which explains why so much scientific effort today focuses on indirect strategies, like the one exploited by **PCAI** compounds via **farnesylation**.

This historic difficulty makes any advance, however modest and preliminary, all the more significant when it manages to effectively disrupt the survival mechanisms tied to this particularly stubborn and widespread mutation among affected **patients**.

*I think it's important to recall why this disease is so frightening, not to dramatize needlessly but so readers understand exactly why a mechanistic advance, even an early one, deserves close attention rather than being ignored.*

## What this could mean for the future of treatment

### A potential new therapeutic class

If the results obtained in the lab hold up through the next stages of research, **PCAIs** could pave the way for a new **class of drugs** specifically targeting cancers driven by **KRAS** mutations, which would extend far beyond **pancreatic cancer** alone to potentially affect other cancers sharing this same problematic mutation.

The authors of the study published in **Oncotarget** themselves note that their data suggest potential for treating cancers driven by different mutant forms of **KRAS**, a lead the scientific community will now need to explore through further, more advanced studies.

### The essential role of continued research funding

This discovery also serves, implicitly, as a reminder of the crucial importance of continued funding for **basic research** in **oncology**, a field where breakthroughs often take years, even decades, to translate into concrete benefits for **patients**, but where every step forward counts in the long accumulation of scientific knowledge.

Without steady institutional support for this kind of work carried out at universities like **Florida A&M**, many promising therapeutic leads would simply never see the light of day, for lack of sufficient resources to carry out the long years of experimentation required.

*I want to stress a point often overlooked in media coverage of scientific discoveries: behind every promising announcement usually lies years of quiet funding and laboratory work far from the spotlight.*

## How to interpret this kind of announcement without illusions

### Distinguishing lab promise from available treatment

For the general public, the distinction between a **laboratory discovery** and an **available treatment** may seem subtle, but it is absolutely fundamental: a compound that kills **cancer cells** in a petri dish is in no way equivalent to an approved, safe and effective drug for humans, a nuance too many sensationalist articles tend to erase.

**Patients** with **pancreatic cancer** and their loved ones, in legitimate search of hope, deserve clear information about what has actually been established scientifically and about what, for now, remains an unvalidated research lead not yet clinically proven in humans.

### The media's role in responsible science communication

Specialized outlets like **ScienceDaily** and **Medical Daily** have, in this respect, done relatively rigorous work by themselves highlighting the limits of this research in their own articles, a practice that in my view should become the norm rather than the exception in journalistic **coverage** of this kind of scientific announcement.

This methodological transparency, including the explicit mention of the **preclinical** stage and realistic timelines before any possible clinical application, is in my view a model to follow for anyone who wants to inform the public without feeding dangerous false hope to people already vulnerable in the face of a difficult **diagnosis**.

*I believe that this rigor in science communication, far more than media sensation, is what truly protects patients from the cruel disillusionment that too often accompanies poorly calibrated announcements.*

## The other research avenues against pancreatic cancer

### A field in constant scientific ferment

**PCAIs** are obviously not the only avenue currently being explored against **pancreatic cancer**: other research teams around the world are working on **immunotherapy** approaches, targeted gene therapy, or new combinations of existing **chemotherapies**, in a collective effort to improve a prognosis that remains, even today, worrying.

This diversity of simultaneous approaches is in itself good structural news: the greater the number of avenues explored, the higher the statistical probability that at least one of them will eventually lead to a concrete clinical breakthrough over years of cumulative research.

### The importance of scientific collaboration

Research on **PCAIs** itself builds on decades of prior work, including studies published as early as the 2010s on similar variants tested against **prostate cancer**, illustrating just how much **science** often advances through gradual accumulation rather than isolated spectacular breakthroughs.

This scientific continuity, which crosses institutional and sometimes national boundaries, deserves to be highlighted as an example of how **basic research** really progresses, far from the simplified narratives of sudden discoveries that obscure the cumulative work of many teams over several years.

*I find it encouraging to see that this discovery fits into a scientific continuity rather than emerging out of nowhere, because that, in my view, reinforces the overall credibility of the effort rather than weakening it.*

## What families feel in the face of these announcements

### Between legitimate hope and necessary caution

For **families** accompanying a loved one with **pancreatic cancer**, every scientific announcement of this kind stirs a complex mix of hope and fear of disillusionment, a feeling I do not claim to know personally but that I deeply respect as a columnist tasked with relaying this information accurately.

This mix of emotions is neither irrational nor excessive: it simply reflects the reality of a daily battle against a disease that leaves little respite, one in which every new scientific lead, however distant, represents a light worth legitimately holding onto.

### The importance of dialogue with medical teams

For **patients** and their loved ones, the best way to interpret this kind of announcement remains discussing it directly with their **treating medical team**, the only ones qualified to assess the relevance of new research leads relative to a specific individual clinical situation, rather than relying solely on popular-science articles, however rigorous they may be.

This recommendation, which I offer with humility, simply aims to remind readers that a columnist's role is to inform and provide context, never to replace the clinical expertise necessary for any concrete therapeutic decision for a given patient.

*I sincerely believe that the greatest respect one can offer families affected by this disease is to speak to them with the same rigorous honesty one would want for oneself in a similar situation.*

## The broader context of oncology research in 2026

### A general acceleration of discoveries

This announcement about **PCAIs** fits into a broader context of accelerated progress in **oncology research**, driven notably by increasingly sophisticated computing tools and biological analysis methods that allow **researchers** to test more compounds in parallel than just a decade ago.

This accelerated pace does not, however, guarantee faster clinical results, since regulatory constraints tied to **patient** safety rightly remain as strict as before, which explains why the gap between laboratory discovery and available **treatment** remains substantial despite technological advances.

### Canada and Quebec's place in this global research

Although this specific study comes from an American university, Canadian and Quebec research teams are actively contributing to similar work on **pancreatic cancer**, as part of a collective international effort where discoveries circulate quickly between laboratories in different countries through shared scientific publications.

This international dimension of the research deserves to be recalled, as it clearly illustrates that the fight against this particularly feared cancer does not depend on a single country or a single team, but on a cumulative global effort to which every new publication, including this one on **PCAIs**, logically adds.

*I find it reassuring to know that this scientific battle is being fought on several continents at once, because that multiplies the chances that a decisive breakthrough will one day emerge from one or another of these laboratories engaged in this shared race.*

## What this discovery reveals about scientific patience

### A lesson in collective humility

Beyond the specific case of **PCAIs**, this story offers a broader lesson about the very nature of scientific research: significant breakthroughs rarely result from a single flash of genius, but rather from patient, methodical, and often invisible work, carried out over long periods by teams who accept uncertainty as a normal condition of their profession.

This reality contrasts sharply with today's media pace, which often favors spectacular announcements at the expense of a more nuanced understanding of the long time needed for any serious and lasting medical advance.

### Why this slowness ultimately protects patients

This apparent slowness, far from being a flaw in the system, actually constitutes essential protection for **patients**: it ensures that only treatments that have demonstrated sufficient **effectiveness** and **safety**, through rigorous **clinical trials**, end up being approved and made available to the public.

Accepting this reality, however frustrating in the face of the urgency felt by **patients** and their **families**, remains in my view the most responsible stance a columnist can take toward this kind of promising but still preliminary scientific news.

*I close this reflection by affirming that scientific patience, however hard it may be to accept emotionally, remains the best guardian of public trust in modern medicine and its legitimate advances.*

## What I hope for the future of this research

### Animal model trials worth watching closely

The next logical step for the teams behind **PCAIs** will be to test these compounds on **animal models**, a crucial phase that will verify whether the effects observed in the lab hold up in a complete living organism, with all the biological complexity that implies compared to simple cell cultures.

This step, if successfully cleared, would pave the way for the first human **clinical trials**, a prospect that, even if it remains distant, deserves to be followed with sustained interest by the medical community and by the general public affected by this disease.

### A responsible journalistic follow-up to continue

As a columnist, I commit to continuing to follow the evolution of this scientific file with the same methodological rigor, avoiding any exaggeration and systematically recalling the full context of this research each time new data is published by the teams involved.

This commitment to factual precision seems to me the least I can offer my readers, particularly on a subject as delicate as one that directly touches the health and hope of many **families** across the country and beyond.

*I personally commit to returning to this story as soon as new results are published, because I believe that rigorously following a scientific lead over time is worth more than ten isolated announcements without context.*

## What this story says about the healthcare system in general

### Basic research, a collective investment

This discovery about **PCAIs** did not come out of nowhere: it rests on a public and academic funding **ecosystem** that, year after year, allows teams like the one at **Florida A&M** to continue work whose concrete results sometimes only materialize after several decades of cumulative effort and renewed grants.

Recalling this budgetary reality is not trivial: every cut to **basic research** funding in **oncology** potentially delays the arrival of treatments like the one that might one day emerge from work on **PCAI** compounds currently being tested against **pancreatic cancer**.

### A shared responsibility between public and private sectors

Further development of these compounds, should they successfully clear preclinical stages, will likely require the involvement of **pharmaceutical** partners capable of financing the costly **phase I**, II and III **clinical trials**, a mandatory step that illustrates the complex collaboration between **academic research** and **industry** needed to turn a laboratory discovery into a drug truly accessible to **patients**.

This interdependence between initial public funding and subsequent private investment deserves to be understood by the general public, because it largely explains why some promising discoveries progress quickly toward the clinic while others, equally valid scientifically, sometimes stall for lack of industrial partners willing to take on the considerable financial risks associated with pharmaceutical development.

*I believe the general public often underestimates just how much funding basic research, far from being an academic luxury, is a direct investment in the medical treatments that we or our loved ones might need in ten or twenty years.*

## Conclusion: an open letter, but hope tempered by caution

### What to take away from this story

Ultimately, this discovery about **PCAI** compounds perfectly illustrates what good scientific news should look like: interesting, methodologically solid, but presented with all the caution its still-early stage of development demands, far from **patients** and pharmacies for now.

The path toward an eventual **treatment** remains long, measured in years if not decades, but every step along that path, including this one, contributes to the gradual accumulation of knowledge that may one day turn a laboratory mechanism into a real therapeutic option for **patients** with this feared cancer.

### One last word of collective humility

I close this letter by recalling that **science** advances through small, rigorous steps rather than sudden miracles, and that it is precisely this methodical slowness, however frustrating for anyone hoping for an immediate solution, that guarantees the reliability of treatments that eventually reach the market decades later.

To the **researchers** at **Florida A&M** and to the entire scientific community working on this file, I simply wish the perseverance needed to turn this promising lead into a tangible clinical advance, in the interest of **patients** who are waiting, sometimes desperately, for better therapeutic options.

*I close this letter with the conviction that measured hope, grounded in verified facts, is worth infinitely more than boundless enthusiasm that would, sooner or later, hurt families more than it claimed to comfort them.*

**By Maxime Marquette, columnist**

## Columnist's transparency note

### Editorial stance

I am not a journalist but a **columnist and analyst**. My expertise lies in observing and analysing the geopolitical, economic and strategic dynamics that shape our world. My work is to take political strategies apart, to understand global economic movements, to put the decisions of international actors in context and to offer analytical perspectives on the changes that are redefining our societies.

I do not claim the cold objectivity of traditional journalism, which stops at reporting facts. **I claim analytical clarity**, rigorous interpretation and a deep understanding of the complex issues that concern us all. My role is to give meaning to the facts, to place them in their historical and strategic context, and to offer a critical reading of events.

### Method and sources

This text keeps the basic distinction between **verified facts and interpretive analysis**. The rule never changes: a factual claim is published only when a verifiable source supports it, and the sources this article actually used are listed under **Sources**, never here.

**Primary source families** used by the publication, when the story has them: official statements from governments and international institutions, public statements by political leaders, reports from intergovernmental organisations, dispatches from recognised international news agencies.

**Secondary source families**: specialised publications, internationally recognised news media, analyses from established research institutions, reports from industry organisations.

When an article cites statistical, economic or geopolitical data, it comes from the institutions that produce it (intergovernmental organisations, central banks, national statistics offices), and the exact institution is named under **Sources**.

### Nature of the analysis

The analyses, interpretations and perspectives in the analytical sections of this article are a **critical, contextual synthesis** based on the information available, the trends observed and the expert comments cited in the sources consulted.

My role is to interpret these facts, to set them in the context of today's geopolitical and economic dynamics, and to give them a coherent meaning within the larger story of the changes shaping our time. These analyses reflect expertise built through continuous observation of international affairs and an understanding of the strategic mechanisms that drive global actors.

This article describes a documented state of affairs on its publication date, not a prediction: later developments may shift its outlook. No update is promised in advance; when an article is corrected or completed, the change is dated in the text.

## Sources

### Primary sources

- [ScienceDaily, Scientists discover an unexpected way to make pancreatic cancer cells self-destruct — June 30, 2026](https://www.sciencedaily.com/releases/2026/06/260622091512.htm)

- [Medical Daily, Scientists Found an Unexpected Way to Make Pancreatic Cancer Cells Self-Destruct — July 3, 2026](https://www.medicaldaily.com/pancreatic-cancer-apoptosis-pcai-self-destruction-research-2026-475904)

- [Oncotarget, The anticancer effects of PCAIs in pancreatic cancer cells involve MAPK and PI3K/AKT pathways hyperactivation — June 3, 2026](https://www.oncotarget.com/article/28879/text/)

### Secondary sources

- [American Journal of Cancer Research, Disruption of actin filaments and suppression of pancreatic cancer cell viability and migration following treatment with polyisoprenylated cysteinyl amides](https://pmc.ncbi.nlm.nih.gov/articles/PMC5126271/)

- [EurekAlert!, The anticancer effects of PCAIs in pancreatic cancer cells involve MAPK and PI3K/AKT pathways hyperactivation — June 8, 2026](https://www.eurekalert.org/multimedia/1134917)

- [National Cancer Institute, general resource on pancreatic cancer](https://www.cancer.gov/)

---

Source: Maxime Marquette, MadMax. When citing, name the author and link https://mad-max.co/en/article/aux-cellules-du-cancer-du-pancreas-qui-apprennent-a-mourir